391 related articles for article (PubMed ID: 17295608)
1. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
2. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation.
Rickels MR; Zhang X; Mumm S; Whyte MP
J Bone Miner Res; 2005 May; 20(5):878-85. PubMed ID: 15824861
[TBL] [Abstract][Full Text] [Related]
3. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ
Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019
[TBL] [Abstract][Full Text] [Related]
4. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.
Ai M; Holmen SL; Van Hul W; Williams BO; Warman ML
Mol Cell Biol; 2005 Jun; 25(12):4946-55. PubMed ID: 15923613
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men.
Kiel DP; Ferrari SL; Cupples LA; Karasik D; Manen D; Imamovic A; Herbert AG; Dupuis J
Bone; 2007 Mar; 40(3):587-96. PubMed ID: 17137849
[TBL] [Abstract][Full Text] [Related]
6. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
7. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
Murrills RJ; Matteo JJ; Bhat BM; Coleburn VE; Allen KM; Chen W; Damagnez V; Bhat RA; Bex FJ; Bodine PV
J Cell Biochem; 2009 Dec; 108(5):1066-75. PubMed ID: 19746449
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of disease-associated polymorphism LRP5.Q89R.
Mao W; Wordinger RJ; Clark AF
Mol Vis; 2011 Apr; 17():894-902. PubMed ID: 21528003
[TBL] [Abstract][Full Text] [Related]
9. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
10. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
12. High bone density due to a mutation in LDL-receptor-related protein 5.
Boyden LM; Mao J; Belsky J; Mitzner L; Farhi A; Mitnick MA; Wu D; Insogna K; Lifton RP
N Engl J Med; 2002 May; 346(20):1513-21. PubMed ID: 12015390
[TBL] [Abstract][Full Text] [Related]
13. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
14. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
[TBL] [Abstract][Full Text] [Related]
15. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
16. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
Semenov MV; He X
J Biol Chem; 2006 Dec; 281(50):38276-84. PubMed ID: 17052975
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification and functional characterization of Wnt signaling co-receptors LRP5 and LRP6.
Fleury D; Vayssiere B; Touitou R; Gillard C; Lebhar H; Rawadi G; Mollat P
Protein Expr Purif; 2010 Mar; 70(1):39-47. PubMed ID: 19716419
[TBL] [Abstract][Full Text] [Related]
18. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
[TBL] [Abstract][Full Text] [Related]
19. An autosomal dominant high bone mass phenotype in association with craniosynostosis in an extended family is caused by an LRP5 missense mutation.
Kwee ML; Balemans W; Cleiren E; Gille JJ; Van Der Blij F; Sepers JM; Van Hul W
J Bone Miner Res; 2005 Jul; 20(7):1254-60. PubMed ID: 15940380
[TBL] [Abstract][Full Text] [Related]
20. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd.
Zhang Y; Wang Y; Li X; Zhang J; Mao J; Li Z; Zheng J; Li L; Harris S; Wu D
Mol Cell Biol; 2004 Jun; 24(11):4677-84. PubMed ID: 15143163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
